Epiomic Epidemiology Series: Glaucoma Forecast in 10 Major Markets 2016-2026

March 2016 | 48 pages | ID: E7FA0E9B057EN
Black Swan Analysis limited

Abstracts

Glaucoma is a term describing a group of eye disorders that result in optic nerve damage. Glaucoma is divided into two main types: open-angle or closed-angle glaucoma. The condition develops when excess aqueous humour is inadequately drained, causing pressure to build. This may damage the optic nerves and the nerve fibres from the retina. There is a progressive loss of retinal ganglion cells and their axons, and the condition can lead to severe sight impairment.

This report provides the current prevalent population for Glaucoma across 10 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Glaucoma have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Glaucoma include:

• Diabetes Mellitus
• Hypertension
• Dyslipidaemia
• Myopia
• Cataracts
• Intraocular hypertension
• Alzheimer’s disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Glaucoma’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Glaucoma and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Glaucoma’s prevalent population.
• Identify sub-populations within Glaucoma which require treatment.
• Gain an understanding of the specific markets that have the largest number of Glaucoma patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/ Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Glaucoma
Features of Glaucoma Patients
  Type and Classification of Glaucoma
  Progressive Glaucoma Co-morbidities
  Non-Progressive Glaucoma Co-morbidities
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

Tests used for glaucoma diagnosis
Prevalence of glaucoma, total (000s)
Prevalence of glaucoma, males (000s)
Prevalence of glaucoma, females (000s)
Type of glaucoma in patients, total (000s)
Severity of glaucoma in POAG patients, total (000s)
BMI of POAG patients, total (000s)
Progressive profile of POAG patients, total (000s)
Type of eye involvement in glaucoma patients, total (000s)
Prevalence of cataracts in progressive glaucoma patients, total (000s)
Prevalence of myopia in progressive glaucoma patients, total (000s)
Prevalence of hypertension in progressive glaucoma patients, total (000s)
Prevalence of diabetes in progressive glaucoma patients, total (000s)
Prevalence of cataracts in non-progressive glaucoma patients, total (000s)
Prevalence of myopia in non-progressive glaucoma patients, total (000s)
Prevalence of hypertension in non-progressive glaucoma patients, total (000s)
Prevalence of diabetes in non-progressive glaucoma patients, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of Glaucoma by 5-yr age cohort, males (000s)
USA Prevalence of Glaucoma by 5-yr age cohort, females (000s)
France Prevalence of Glaucoma by 5-yr age cohort, males (000s)
France Prevalence of Glaucoma by 5-yr age cohort, females (000s)
Germany Prevalence of Glaucoma by 5-yr age cohort, males (000s)
Germany Prevalence of Glaucoma by 5-yr age cohort, females (000s)
Italy Prevalence of Glaucoma by 5-yr age cohort, males (000s)
Italy Prevalence of Glaucoma by 5-yr age cohort, females (000s)
Spain Prevalence of Glaucoma by 5-yr age cohort, males (000s)
Spain Prevalence of Glaucoma by 5-yr age cohort, females (000s)
United Kingdom Prevalence of Glaucoma by 5-yr age cohort, males (000s)
United Kingdom Prevalence of Glaucoma by 5-yr age cohort, females (000s)
Brazil Prevalence of Glaucoma by 5-yr age cohort, males (000s)
Brazil Prevalence of Glaucoma by 5-yr age cohort, females (000s)
Japan Prevalence of Glaucoma by 5-yr age cohort, males (000s)
Japan Prevalence of Glaucoma by 5-yr age cohort, females (000s)
India Prevalence of Glaucoma by 5-yr age cohort, males (000s)
India Prevalence of Glaucoma by 5-yr age cohort, females (000s)
China Prevalence of Glaucoma by 5-yr age cohort, males (000s)
China Prevalence of Glaucoma by 5-yr age cohort, females (000s)